Citations

Clear

3057 citation(s) found for "Cd, Johnson".

An Orally Available Grafted Peptide Targeting Epidermal Growth Factor Receptor Dimers Reduces Non-Small Cell Lung Cancer Tumors in Mouse Models
Shrestha, Prajesh , Dahal, Achyut, Chowdhury, Arpan , Majumdar, Debajyoti, Gu, Xin , Johnson, William W., Zhang, Dachuan , Billadeau, Daniel D. , Jois, Seetharama D. , Zhang, Dachuan , Jois, Seetharama , Singh, Sitanshu S. , Prasasty, Vivitri Dewi , Johnson, William

Mayo Clinic

ACS Pharmacology & Translational Science | September 9, 2025 | Volume: 8 | Issue: 10 | Pages: 3531-3545

10.1021/acsptsci.5c00336 | PMID 41098571 Get It

A Neurosurgeon's Guide to Mobile Health Application Development With a Case Study for Cervical Myelopathy
Singh, Pranay , Chen, Erdong, Steel, Ben , Chicoine, Nicolas, Yakdan, Salim, Bydon, Mohamad, Steinmetz, Michael P. , Ray, Wilson Z. , Johnson, Brian P. , Duncan, Ryan P. , Wilt, Zachary , Kelleher, Caitlin , Greenberg, Jacob K , Chen, Erdong, Steel, Benjamin, Yakdan, Salim M. , Bydon, Mohamad , Ghogawala, Zoher , Badhiwala, Jetan H.

Mayo Clinic

Neurosurgery | September 9, 2025 | Volume: 98 | Issue: 4 | Pages: 726-736

10.1227/neu.0000000000003717 | PMID 40923792 Get It

The integration of mobile health (mHealth) technologies is transforming neurosurgery. Despite its potential, many uses remain unrealized due to the unique challenges and complexity of developing mHealth technology. While neurosurgeons bring invaluable clinical expertise and an understanding of patient needs, the technical intricacies of application development often require collaboration with developers and computer scientists, a process that can feel unfamiliar and difficult to navigate. The aim of this article was to demystify mHealth development by providing a guide for neurosurgeons seeking to develop disease-specific mHealth applications. We outline this process using the development of SynapTrack, an mHealth tool designed to provide objective assessments of degenerative cervical myelopathy, a chronic condition caused by symptomatic compression of the cervical spinal cord. This article offers neurosurgeons concrete guidance on navigating key considerations such as design decisions, algorithm integration, database architecture, and data security. By grounding these insights with SynapTrack, this guide offers a transparent view into the development process and provides a practical framework that can be adapted to the development of other mHealth tools. The aim of this work was to foster interdisciplinary collaboration and enable neurosurgeons to develop mHealth applications tailored to the specific needs of their specialty.
Sulcal morphology in former American football players
Jung, Leonard , Mirmajlesi, Anya S, Stearns, J. W. , Breedlove, Katherine M. , John, Omar , Kim, Nicholas , Wickham, Alana, Protas, Hillary , Baucom, Zachary, Tuz‐Zahra, Fatima , Wiegand, Tim L. T. , Billah, Tashrif , Pasternak, Ofer, Im, Brian , Datta, Shae , Bernick, Charles , Balcer, Laura J. , Alosco, Michael L. , Lin, Alexander , Cummings, Jeffrey L., Reiman, Eric M. , Arciniega, Hector , Boker, Connie, Kowall, Neil W. , Otis, James , Weller, Jason , Simkin, Irene, Andino, Alondra, Diamond, Courtney , Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen , Nanna, Mary, Platt, Taylor, Rice, Fiona, Sestak, Madison, Annis, Douglas S. , Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Martin, Brett, Palmisano, Joseph , Pine, Brittany, Fitzsimmons, Jennifer, Pasternak, Ofer , Arcinieago, Hector, Coello, Eduardo , Coleman, Michael J. , Jung, Leonhard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah J. , Ritter, Aaron, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Falk, Bryce W., Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Marmar, Charles R. , Hasanaj, Lisena, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan , Martin, Sammie, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth A. , Marcus, Daniel S., Gurney, Jenny , Greenwald, Richard M., Johnson, Keith A. , Jung, Leonard B , Stearns, Jared , Breedlove, Katherine , Tripodis, Yorghos , Adler, C H , Alosco, Michael L , Koerte, Inga K , Arciniega, Hector , Su, Yi , Tripodis, Yorghos , Daneshvar, Daniel H. , Heller, Carina , Coleman, Michael , Adler, Charles H. , Stern, Robert A. , Shenton, Martha E. , Bouix, Sylvain , Chen, Kewei , Au, Rhoda , Cantu, Robert C. , Farrer, Lindsay A. , Helm, Robert H. , Katz, Douglas I. , Mez, Jesse , Mercier, Gustavo , Conneely, Shannon E. , Diamond, Courtney, Pulukuri, Surya Vamsi , McClean, Michael D , Annis, Douglas, Chaisson, Christine E. , Finney, Carolyn, Lü, Jun , Ojo, Emmanuel, Ramachandran, Janani , Bonke, Elena M. , Miller, Jason Rafe , Sabbagh, Marwan Noel , II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Wethe, Jennifer V. , Falk, Bryce, Montague, Michelle, Bellgowan, Patrick S.F. , Barr, William , Goldberg, Judith D. , Wısnıewskı, Thomas , Kirov, Ivan I. , Lui, Yvonne W. , George, Allan, Riley, Edward P. , Cummings, Jeffrey L.

Mayo Clinic

Brain Communications | September 9, 2025 | Volume: 7 | Issue: 5 | Pages: No page available

10.1093/braincomms/fcaf345 | PMID 41048544 Get It

Abstract Repetitive head impacts are associated with structural brain changes and an increased risk for chronic traumatic encephalopathy, a progressive neurodegenerative disease that can only be diagnosed after death. Chronic traumatic encephalopathy is defined by the abnormal accumulation of phosphorylated tau protein, particularly at the depths of the superior frontal sulci, suggesting that sulcal morphology may serve as a relevant structural biomarker. Contact sport athletes, such as former football players, are at elevated risk due to their prolonged exposure to repetitive head impacts. Cortical atrophy linked to underlying tau accumulation may result in shallower and wider sulci, potentially making sulcal morphology an imaging marker for identifying individuals at risk for this disease. This study investigated sulcal morphological differences in former football players and examined associations with age, football-related exposure, clinical diagnosis of traumatic encephalopathy syndrome, levels of certainty for chronic traumatic encephalopathy pathology, neuropsychological performance, and positron emission tomography imaging using flortaucipir. We analysed structural magnetic resonance imaging data from 169 male former football players (mean age 57.2 (8.2) years, range 45–74) and 54 age-matched, unexposed asymptomatic male controls (mean age 59.4 (8.5) years, range 45–74). Sulcal depth and width were quantified using the CalcSulc, focusing on two regions in each hemisphere commonly affected by chronic traumatic encephalopathy pathology: the superior frontal and occipitotemporal sulci. Generalized least squares models were used to assess group differences and interactions with age and football exposure variables, including age of first exposure, total years played, and cumulative head impact exposure. An analysis of covariance evaluated relationships between sulcal morphology, clinical measures, and flortaucipir uptake, adjusting for age, race, body mass index, education, imaging site, apolipoprotein E4 status, and total intracranial volume. Former football players demonstrated significantly shallower sulcal depth in the left superior frontal sulcus compared to unexposed controls. Earlier age of first exposure and longer football careers were associated with greater widening of the left occipitotemporal sulcus. Higher cumulative head impact exposure was linked to reduced sulcal depth in the left superior frontal region. However, sulcal morphology was not associated with clinical diagnosis, levels of certainty, neuropsychological test performance, or flortaucipir imaging. These findings suggest that sulcal morphology may reflect cumulative exposure to repetitive head impacts, particularly in brain regions vulnerable to chronic traumatic encephalopathy pathology. Future ante- and post-mortem validation studies are needed to determine whether sulcal morphology can serve as a reliable in vivo biomarker of risk.
A Comparative Study of Quality of Life and Oncologic Outcomes in Premenopausal Women with Hormone Receptor-Positive Breast Cancer: Bilateral Oophorectomy vs. Gonadotropin-Releasing Hormone Agonist Therapy
Erdemoğlu, Evrim , Ruddy, Kathryn J. , Buras, Matthew , Quillen, Jaxon , Larson, Nicole L. , Yi, Johnny , Butler, Kristina , Buras, Matthew R , Larson, Nicole , Butler, Kristina A., Ruddy, Kathryn J , Quillen, Jaxon K , Couch, Fergus J. , Olson, Janet E. , Bozzuto, Laura

Mayo Clinic

Cancers | September 5, 2025 | Volume: 17 | Issue: 17 | Pages: 2916

10.3390/cancers17172916 | PMID 40941013 Get It

Background/Objectives: This study aims to evaluate the quality of life (QoL) and oncological outcomes in premenopausal women diagnosed with hormone receptor-positive breast cancer who are receiving either bilateral oophorectomy (BO) or gonadotropin-releasing hormone agonist (GnRH) therapy. Both methods serve to inhibit ovarian function, which is essential for the management of estrogen-dependent tumors; however, their effects on QoL have yet to be fully clarified. Methods: Data were analyzed from the Mayo Clinic Breast Disease Registry, focusing on women under 55 diagnosed with estrogen receptor-positive breast cancer who received either BO or GnRH within one year of diagnosis. QoL was assessed using the Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10) at baseline and annually for five years. Results: A total of 181 patients were enrolled in the study; 40 into the BO group and 141 to the GnRH group. Both groups exhibited similar levels of sexual dysfunction after a one-year period; however, the BO group stated a higher frequency of hot flashes. PROMIS-10 scores improved in both mental and physical health over time, with no significant differences between the groups. Within the BO group, one recurrence was observed, in contrast to the GnRH group, which had six events. Nonetheless, the difference in recurrence rates did not reach statistical significance. Conclusions: The long-term QoL and oncologic outcomes for premenopausal women with hormone receptor-positive breast cancer were similar for BO and GnRH therapy. These findings emphasize the need for individualized treatment decisions, considering patient preferences and side effects.
Challenges in the return of molecular tumor profiling results
Lenz, Heinz-Josef, Craig, David W. , Johnson, Kevin C. , Verhaak, Roel G.W. , Bhattacharyya, Oindrila , Davis, Bethany , Wesley, C. John, Byron, Sara A. , Willman, Cheryl L. , Kelley, Lindsey , Claus, Elizabeth B. , Trent, Jeffrey M. , Culver, Julie O. , Church, Alanna J. , Lenz, Heinz-Josef , Verhaak, Roel Gw , Willman, Cheryl , Trent, Jeffrey M , Gray, Stacy W , Church, Alanna J , Wesley, Cherie, Kelley, Lindsey , Claus, Elizabeth B , Gray, Stacy W.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 5, 2025 | Volume: 118 | Issue: 5 | Pages: 776-782

10.1093/jnci/djaf251 | PMID 40929086 Get It

Abstract Next-generation sequencing has transformed cancer care by providing essential insights for diagnosis, prognosis, and treatment. However, variability in testing timing, reporting practices, and interpretation challenges limits its clinical impact. This article highlights key opportunities to optimize somatic reporting, emphasizing the importance of timely testing throughout the cancer care continuum to maximize the diagnostic and therapeutic relevance of findings. Technical factors such as test design, sequencing depth, and the use of liquid biopsy substantially influence result accuracy and interpretation, underscoring the need for careful integration with clinical history. Standardized reporting practices that clearly delineate diagnostic, prognostic, and therapeutic findings can enhance the clinical utility of next-generation sequencing results. Streamlined formats and curated clinical trial data further support actionable decision making. Additionally, direct patient engagement and education are essential for empowering patients to navigate genomic testing and make informed decisions about their care. By leveraging multidisciplinary tumor boards, decision-support tools, and emerging artificial intelligence technologies, clinicians can better navigate the complexities of somatic reports. Standardization and clarity in reporting are critical to advancing precision oncology, empowering providers and patients to make informed treatment decisions and improve outcomes.
ACR–ABS–ACNM–ARS–SIR–SNMMI Practice Parameter for Radioembolization of Liver Malignancies
Johnson, Thor, Spieler, Benjamin , Toskich, Beau , Wang, David S. , Russo, Suzanne , Sharma, Navesh , Wright, Chadwick , Farsad, Khashayar , Muzahir, Saima , Chundury, Anupama , Subramaniam, Rathan M. , Caplin, Drew M. , Schechter, Naomi R., Toskich, Beau B. , Hathout, Lara , Russo, Suzanne , Kim, Charles , Kappadath, Srinivas Cheenu , Parent, Ephraim E. , Sio, Terence T. , Mercier, Gustavo , Ghesani, Munir V. , Small, William

Mayo Clinic

American Journal of Clinical Oncology | September 3, 2025 | Volume: 49 | Issue: 1 | Pages: 10-24

10.1097/coc.0000000000001234 | PMID 40899409 Get It

Objectives: The practice parameter was revised collaboratively by the American College of Radiology (ACR), the American Brachytherapy Society (ABS), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), the Society of Interventional Radiology (SIR), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). This document summarizes current evidence-based guidelines for the administration of Yttrium radioembolic therapy to the liver, including training requirements, evidence-based guidelines for administration, and safe practice for administration. Methods: This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/ClinicalResources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters—Interventional and Cardiovascular Radiology of the ACR Commission on Interventional and Cardiovascular, Committee on Practice Parameters and Technical Standards—Nuclear Medicine and Molecular Imaging of the ACR Commission on Nuclear Medicine and Molecular Imaging and the Committee on Practice Parameters—Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with the ABS, the ACNM, the ARS, the SIR, and the SNMMI. Results: This review seeks not to be a comprehensive discussion of radiotherapy to the liver, but rather, seeks to provide a parameter for safe and effective therapy. We discuss the qualifications of physicians involved in this therapy, basic indications, contraindications, procedural work-up, safe-handling, and regulatory requirement for the administration of selective internal radiation therapy to patients that are likely to benefit. The goal of this document is not to define which patients are best treated by these therapies, as this is best determined for individual patients after multidisciplinary review. A consistent and evidence-based approach to therapy, however, would benefit all patients who are offered this therapy. This document seeks to provide a framework for current best practices for the administration of the 2 currently available radioembolization devices. Conclusions: As Yttrium-90 radiotherapy to the liver occupies a growing role in the treatment of primary and metastatic liver cancer, this review seeks to assist clinicians of all involved specialties to optimize the efficacy and safety of these procedures.
Editorial Comment
Johnson, Olivia A., Findlay, Bridget L. , Johnson, Olivia A.

Mayo Clinic

Journal of Urology | September 3, 2025 | Volume: 214 | Issue: 6 | Pages: 652-653

10.1097/ju.0000000000004735 | PMID 40899501 Get It

AI to the Rescue: Fighting Atrial Fibrillation With Code
Mangold, Kathryn, Johnson, Linda S.B. , Deshmukh, Abhishek , Mangold, Kathryn E , Johnson, Linda S B , Deshmukh, Abhishek

Mayo Clinic

Journal of Cardiovascular Electrophysiology | August 28, 2025 | Volume: 36 | Issue: 11 | Pages: 2816-2817

10.1111/jce.70084 | PMID 40872998 Get It

Low Measles Seropositivity in Vaccinated Children
Jones, Sara Pace, Joseph, Iype, Powell, Alexandria J., Ovsyannikova, Inna G. , Warner, Nathaniel D. , Grill, Diane E. , Sasi, Remya Vasanthi, Ajithakumari, Archana Mohankumar, Prasad, Raji, Reveendran, Remya, Devakikutty, Jayalekshmi, Mohanakumari, Vishnu Vikraman, Poland, Gregory A., Pillai, M. Radhakrishna , Jacob, Joshy , Quach, Huy Quang , Kennedy, Richard B. , Jones, Sara P., Powell, Alexandria J., Johnson, John Bernet , Mohanakumari, Vishnu VikramanThampi, Poland, Gregory A.

Mayo Clinic

JAMA Network Open | August 27, 2025 | Volume: 8 | Issue: 8 | Pages: e2529409

10.1001/jamanetworkopen.2025.29409 | PMID 40864465 Get It

ImportanceIndia’s goal of measles elimination remains unmet, as evidenced by significant recent outbreaks.ObjectiveTo identify seroprevalence rates among vaccinated children and to examine demographic factors that influence antibody responses.Design, Setting, and ParticipantsThis cross-sectional study included a highly vaccinated cohort of Indian children from the states of Kerala and Tamil Nadu between 2018 and 2023. Eligible children had received at least 2 doses of measles-containing vaccines; their mothers were recruited from various community settings, including local nursery and secondary schools, residential associations, and hospitals.ExposureMeasles-specific antibodies were quantified in serum samples.Main Outcomes and MeasuresMeasles-specific immunoglobulin G (IgG) and neutralizing antibodies were quantified in both children and mothers. Measles-specific IgM was also measured in children.ResultsThe total cohort comprised 684 children (median age, 9 years [range, 4-18 years]; 348 male [50.1%]) and 544 mothers. All children received at least 2 doses of measles-containing vaccines; 435 children (63.6%) received a third dose, and 7 (1.0%) received a fourth dose. Among the children, 621 (90.8%) had positive measles-specific IgG, and 623 (91.5%) had protective neutralizing antibodies titers, with a strong correlation between measles-specific IgG and neutralizing antibodies (r = 0.73; P < .001). Female children exhibited significantly higher titers of both measles-specific IgG and neutralizing antibodies compared with male children. While IgG and neutralizing antibody titers remained stable over time and were not associated with the number of vaccine doses in children, neutralizing antibody titers increased with age in mothers, likely due to repeated viral exposure. Notably, in 20 families with at least 2 children, differential measles-specific IgM profiles were observed between siblings despite high IgG and neutralizing antibody titers, suggesting ongoing breakthrough infections.Conclusions and RelevanceIn this cross-sectional study, substantial measles immunity gaps were found despite high vaccine coverage with evidence of breakthrough infections, posing significant challenges to India’s measles elimination efforts. These results underscore the urgent need to strengthen India’s immunization program and investigate the mechanisms driving suboptimal responses to measles vaccination; without addressing these immune response deficiencies, achieving measles elimination through increased vaccine coverage alone may remain unattainable in India.
Safety and Efficacy Findings From a Phase Ib/ II Study of ASP ‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squ
Cognetti, David M. , Johnson, Jennifer M. , Kwon, Michael , Su, Shirley Y. , Civantos, Francisco , Valentino, Joseph, Bell, R. Bryan, Abel, Kathryn M. Van , Price, Katharine A. , Dong, Haiying, Thorne, Amy Haseley, Van Abel, Kathryn M , Su, Shirley Y , Curry, Joseph , Olazagasti, Coral , Arnold, Susanne M. , Gibson, Michael K. , Mannion, Kyle , Suzuki, Toshiaki , Gillenwater, Ann Marie

Mayo Clinic

Head & Neck | August 25, 2025 | Volume: 48 | Issue: 1 | Pages: 160-174

10.1002/hed.70014 | PMID 40852760 Get It

ABSTRACT Background ASP‐1929 photoimmunotherapy—cetuximab conjugated to IRDye 700DX and red light (690 nm) for localized drug activation—results in rapid, selective cell killing. Methods This phase Ib/II open‐label study evaluated ASP‐1929 photoimmunotherapy plus pembrolizumab in patients with recurrent/metastatic HNSCC (≥ 1 accessible lesion, PD‐L1 combined positive score ≥ 1, ineligible for standard locoregional therapy). Primary objectives were safety/tolerability and objective response rate (ORR). Secondary objectives included overall survival (OS) and progression‐free survival (PFS). Results Eighteen patients (median age 63 years, 74% male) comprised the photoimmunotherapy‐evaluable population. The confirmed ORR was 27.8% (95% CI 9.7–53.5); four of five responders had complete responses (95% CI, 6.4–47.6). Median OS was 25.6 months (95% CI, 14.6–not evaluable); median PFS was 2.9 months (95% CI, 1.4–14.6). The most common serious adverse reactions were dysphagia and tongue edema (each n = 2; 10.5%). Conclusions ASP‐1929 photoimmunotherapy plus pembrolizumab was generally tolerable, with promising efficacy in patients with recurrent/metastatic HNSCC.